-- 週四,加拿大皇家銀行資本市場(RBC Capital Markets)、加拿大帝國商業銀行資本市場(CIBC Capital Markets)和道明證券(TD Securities)的分析師上調了Aecon集團(ARE.TO)的目標價。 這家加拿大建築和基礎設施公司於週三公佈了第一季業績。 Aecon股價在多倫多證券交易所上漲1.87加元,漲幅3.9%,收在49.97加元。 加拿大皇家銀行分析師Sabahat Khan將該股的目標股價從44加幣上調至49加元,並維持「與產業持平」的評級。 Khan在給客戶的報告中表示:“總體而言,2026年開局良好,創紀錄的109億美元積壓訂單為公司發展創造了有利條件。” “隨著營收持續增長,中期內,我們將密切關注利潤率的提升(隨著公司逐步擺脫傳統項目的影響)。” 加拿大帝國商業銀行分析師Krista Friesen將該股的目標價從48加元上調至52加元,並維持「中性」評級。 弗里森在給客戶的報告中表示:“我們認為(週三的)股價波動反映出投資者關注點已從近幾個季度困擾公司的運營問題轉向未來的機遇。” 道明銀行分析師邁克爾·圖普霍爾姆將目標價從59美元上調至62美元,並維持「買進」評級。 圖普霍爾姆在給客戶的報告中表示:“隨著遺留項目風險基本消除,以及業務結構持續向結構性有吸引力的終端市場轉型(儘管ARE的估值尚未完全反映這一點),我們預計其估值將進一步上調。” “與擁有類似吸引力的終端市場敞口的美國同行相比,ARE的股價仍然存在顯著折讓。”
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%